Basic Information of Fezolinetant
- Product name:Fezolinetant
- IUPAC:(4-fluorophenyl)-[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]methanone
- InChI Key:PPSNFPASKFYPMN-SECBINFHSA-N
- CAS :1629229-37-3
- Molecular formula：C₁₆H₁₅FN₆OS
- Molecular weight：39 g/mol
Fezolinetant: Key Technical & Clinical Overview
- Appearance: White to off-white powder / crystalline solid
- Reference Product Brand Name: Veozah
- FDA Approval Year: 2023
- Drug Class: Neurokinin-3 Receptor Antagonist (NK3RA)
- Indications: For the treatment of moderate to severe vasomotor symptoms (hot flashes) associated with menopause
- Dosage Form / Strength: Oral tablets, 45 mg
What is Fezolinetant？
Fezolinetant definition: Fezolinetant (CAS 1629229-37-3) is a neurokinin 3 (NK3) antagonist.It is primarily used for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.Its formulation is a non-hormonal medication that can significantly reduce the frequency and severity of hot flashes and night sweats in menopausal women.
Fezolinetant Mechanism of Action: By competitively binding to NK3 receptors, fezolinetant blocks NKB from activating the receptors, thereby restoring stability to thermoregulation and providing rapid, significant relief from VMS symptoms.
Patent Information & Compliance Statement
- Patent Information & Compliance Statement
| Item | Sample Content |
| Core Compound Patents | US10414726B2, WO2017/220957A1, etc. |
| Patent Expiry | US: 2031–2034; China: 2026 |
| Bolar Exception Clause | Pursuant to Article 75(V) of the Patent Law of the People’s Republic of China, research quantities may be supplied for administrative examination and approval purposes. |
| Buyer’s Liability Statement | The buyer shall independently assess the patent status of the target market and bear corresponding legal responsibilities. |
Citing the “Bolar Exemption,” supply is strictly limited to uses such as research and development (R&D) and regulatory filing purposes.
Orders start at the milligram scale, designed to support your R&D requirements.
Our manufacturing facility complies with GMP standards and operates under a comprehensive quality management system.
A Certificate of Analysis (COA) is provided with every shipment; if you require additional spectral data—such as HPLC, NMR, or MS charts—please contact our customer service team to request them.
Fezolinetant Reference Standards & R&D Materials
We offer Fezolinetant powder in various purity grades to meet the needs of different stages of generic drug development, including project initiation, process development, impurity profiling, and Preparation for Declaration.Choose the right grade according to your project phase and budget.
Research Grade Fezolinetant（≥98%）
- Applicable Stages: Early-stage Project Initiation, Synthesis Route Exploration, Patent Research
- Recommended Scale: Gram-scale to Tens of Grams
- Applications: Laboratory Bench-scale Trials, Feasibility Assessment
API/Registration Grade Fezolinetant（≥99%）
- Applicable Stages: Late-stage process validation, small-scale formulation studies, preparation of DMF/CTD submission dossiers (establishment of quality standards)
- Recommended Quantities: 100 g – 1 kg
- Applications: Pilot-scale up, raw materials for registration batches, stability studies
Impurity Reference Standard Fezolinetant（≥95%,Single Impurity）
- Applicable Stages: Analytical Method Development, Impurity Profiling, QC Method Validation
- Recommended Scale: Milligram to Gram Scale
- Applications: HPLC Method Development, Impurity Identification, System Suitability
Advantages of Highassay
Highassay is a reliable supplier of Fezolinetant raw materials from China.
15+ Years of Experience
Over 15 years in the pharmaceutical raw material sector, providing stable supply services to over 100 companies.
Comprehensive Product Portfolio & Service
With our extensive products and end-to-end service capabilities, we have earned the long-term trust of numerous clients through our consistent delivery performance and professional responsive support.
Professional Logistics & Project Coordination
Our team is capable of efficiently handling issues related to supply chain coordination, compliance interfacing, and logistics execution.You simply need to focus on the R&D itself—saving you both time and effort.
Elinzanetant vs Fezolinetant
| Item | Elinzanetant | Fezolinetant |
| Originator Company | Bayer / Otsuka | Astellas |
| Brand Name | Not yet available (in clinical development) | Veozah |
| CAS No. | 2102097-93-6 | 1629229-37-3 |
| Molecular Formula | C₂₀H₁₉FN₆O₂S | C₁₆H₁₅FN₆OS |
| Molecular Weight | 426.47 g/mol | 358.39 g/mol |
| FDA Approval Status | Phase 3 clinical stage (not yet approved) | Approved in May 2023 |
